Financial Results for the First Quarter of
Fiscal Year Ending March 31, 2024 (FY2023)

from the beginning

Financial Results for the First Quarter of Fiscal Year Ending March 31, 2024 (FY2023)

• Forward-Looking Statements and Use of Document

• Highlights

• P&L

• Margin Ratio Recovery from FY22 Q4

• Operating Profit Variance Analysis

• Profitability Improvements Included in FY23 Annual Guidance

• Profitability Improvement Progress

• Revenue by Region

• C&V: EU, US drove strong sales; profit progress as planned

• TMCS: Sell-off of nutrition business, PS delivery fluctuations impacts.Reduced sales, profit; however, progress as planned toward annual guidance

• TBCT: Large profit increase driven by solid sales to blood centers

• 20B JPY Share Repurchase Decision by the Board, as of Aug 9th

Reference

• Revenue by Segment and Region

• Revenue and Operating Profit Quarterly Trend

• Margin Ratio Recovery from FY22 Q4

• P&L (QoQ)

• SG&A (QoQ)

• SG&A (YoY)

• Adjusted Operating Profit: Adjustments

• CAPEX, Depreciation and R&D Expenses

• Cash Flows (Q1)

• FY23 Q1 FX Impact Breakdown (Flow, Stock)

• Foreign Exchange Sensitivity

• Product Pipeline

@